AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03922711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04080349
Drug: Dinoprostone 3 mg
RxNorm normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Trial: NCT04080349
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Trial: NCT03167034
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT02639286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via SC
Trial: NCT00925899
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
Trial: NCT00925899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
Trial: NCT05680389
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily for 3 months
Trial: NCT05680389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 3 months
Trial: NCT00338442
Drug: VariZIG™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological / Vaccine
Trial: NCT03019614
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Generic hydrocortisone
Trial: NCT03019614
Drug: Chronocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified formulation of hydrocortisone
Trial: NCT03038321
Drug: sofenacin
RxNorm normalized name: solfenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
Trial: NCT03038321
Drug: Xefo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Trial: NCT03011788
Drug: Golytely Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel purge prior to,colonoscopy
Trial: NCT00730158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
Trial: NCT03157401
Drug: intravenous infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Trial: NCT03157401
Drug: intra-articular injection group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
Trial: NCT03157401
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Trial: NCT01958866
Drug: Tinospora Crispa-extract Product
RxNorm normalized name: Tinospora cordifolia whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01958866
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00516321
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo taken once daily orally
Trial: NCT02447965
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
Trial: NCT02865681
Drug: HCG trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable
Trial: NCT03880058
Drug: SLI-F06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment
Trial: NCT00497991
Drug: AZD1152
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03262935
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See drug label
Trial: NCT03428958
Drug: NUC-3373 + leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + leucovorin
Trial: NCT03428958
Drug: NUFOX + VEGF pathway inhibitor
RxNorm normalized name: Hedgehog pathway inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + oxaliplatin + bevacizumab
Trial: NCT03428958
Drug: NUFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + irinotecan
Trial: NCT03428958
Drug: NUFIRI + VEGF pathway inhibitor
RxNorm normalized name: Hedgehog pathway inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-3373 + irinotecan + bevacizumab
Trial: NCT01507038
Drug: YH14617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6mg once weekly
Trial: NCT01507038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly
Trial: NCT03880058
Drug: Formulation buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT00549640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
Trial: NCT01599104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to LCZ696 or Olmesartan
Trial: NCT00091650
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01477073
Drug: FSH-GEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01477073
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01477073
Drug: urinary FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01477073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03628391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for ICU delirium, titrated on validated screening tool-based diagnosis
Trial: NCT00636155
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2 on days 2, 3, and 4
Trial: NCT01715168
Drug: DOXIL/CAELYX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004654
Drug: soy protein isolate
RxNorm normalized name: Soy Protein Isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02705755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02382328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
Trial: NCT00141349
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00226772
Drug: OMS103HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
Trial: NCT00226772
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Trial: NCT01303445
Drug: Aggrenox alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggrenox 1 capsule twice daily for 7 days
Trial: NCT02014129
Drug: LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02186769
Drug: Risperdal® Consta®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02186769
Drug: LY03004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04667780
Drug: Standard COVID-19 care
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per the hospital guidelines
Trial: NCT02182323
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00779181
Drug: ADX415
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX415 taken three times a day to achieve a low total daily dose
Trial: NCT00779181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken three times a day
Trial: NCT02371980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT01992900
Drug: eurartesim film coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
Trial: NCT03780686
Drug: Norepinephrine, dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drugs to decrease bleeding
Trial: NCT04315298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Trial: NCT00542789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily oral
Trial: NCT03647969
Drug: mFOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
Trial: NCT00654394
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00131638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
Trial: NCT00175292
Drug: Probiotic - VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02568735
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
Trial: NCT04393675
Drug: LT5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily
Trial: NCT04393675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily
Trial: NCT00025597
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025597
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00142558
Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01456286
Drug: sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
Trial: NCT00142558
Drug: Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02089178
Drug: sevoflurane-remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01134237
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline as a placebo for control arm
Trial: NCT00599716
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
Trial: NCT02847702
Drug: VM902A 200-mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally with food twice daily
Trial: NCT00325949
Drug: Extended release hydrocodone and acetaminophen (Vicodin CR)
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets BID
Trial: NCT00325949
Drug: hydrocodone/acetaminophen extended release (Vicodin CR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet BID
Trial: NCT00325949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets BID
Trial: NCT02216669
Drug: DTP348
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
Trial: NCT01609348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule matching active drug to be taken once a day for 12 weeks
Trial: NCT02847702
Drug: VM902A 400-mg Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally with food twice daily
Trial: NCT02847702
Drug: Naproxen 500-mg Capsules
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally with food twice daily
Trial: NCT02847702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules to match VM902A and/or naproxen taken orally with food twice daily
Trial: NCT01122901
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01998906
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3
Trial: NCT01998906
Drug: CMF
RxNorm normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Trial: NCT00428519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days
Trial: NCT01061203
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 75.000 SQ-T once daily
Trial: NCT01061203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet with no active grass component.
Trial: NCT00473902
Drug: Creatine Monohydrate, Conjugated Linoleic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02473419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00477776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
Trial: NCT00886951
Drug: I123MNI388/I123MNI390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
Trial: NCT02403596
Drug: Exacyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00761709
Drug: AL-39256 Ophthalmic Suspension, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00761709
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo comparator
Trial: NCT01185782
Drug: Gonalef® (Follitropin alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Trial: NCT01351493
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide Gel, once or twice per day, 12weeks
Trial: NCT01351493
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo Gel, once or twice per day, 12weeks
Trial: NCT00648544
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 80 mg oral immediate-release tablet
Trial: NCT00648544
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 80 mg oral immediate-release tablets
Trial: NCT01447654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg for 12 months.
Trial: NCT04046328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-Coated Delayed Release Placebo Capsules
Trial: NCT04032067
Drug: GV1001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % Normal Saline
Trial: NCT04032067
Drug: Proscar placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT00004164
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004164
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04412577
Drug: TQB3473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
Trial: NCT01138423
Drug: Placebo (for aliskiren)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Trial: NCT01609491
Drug: norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
Trial: NCT00865436
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Trial: NCT00171184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily with sham titration
Trial: NCT01860664
Drug: hydrocortisone ophthalmic ointment 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone
Trial: NCT01860664
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil and white petrolatum
Trial: NCT01852071
Drug: PEG-ADA ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Trial: NCT02735239
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally-administered chemotherapy
Trial: NCT02735239
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemo-protective agent
Trial: NCT00240929
Drug: MEDI-493
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT00017225
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00017225
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no